title: How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies.
abstract: In the last five years, everolimus has demonstrated efficacy in the treatment of neuroendocrine tumors (NETs) of different origins; its efficacy and safety were explored in the RADIANT trials, the last of which (RADIANT-4) has been recently published (December 2015). Overall, evidence collected from the RADIANT studies holds promise to change clinical practice for the treatment of NETs.In this paper, we comment on the role of everolimus within the therapeutic algorithm for NETs treatment, based on the systematic analysis of the RADIANT trials and our experience.
authors.affiliation: Medical Oncology Department, ENETs Center of Excellence, Milan, Italy.|Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
authors.forename: Sara
authors.initials: S
authors.lastname: Pusceddu
authors.affiliation: Medical Oncology Department, ENETs Center of Excellence, Milan, Italy.|Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
authors.forename: Filippo
authors.initials: F
authors.lastname: De Braud
authors.affiliation: Medical Oncology Department, ENETs Center of Excellence, Milan, Italy.|Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Lo Russo
authors.affiliation: Medical Oncology Department, ENETs Center of Excellence, Milan, Italy.|Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
authors.forename: Laura
authors.initials: L
authors.lastname: Concas
authors.affiliation: Medical Oncology Department, ENETs Center of Excellence, Milan, Italy.|Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
authors.forename: Daniela
authors.initials: D
authors.lastname: Femia
authors.affiliation: Medical Oncology Department, ENETs Center of Excellence, Milan, Italy.|Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
authors.forename: Claudio
authors.initials: C
authors.lastname: Vernieri
authors.affiliation: Medical Oncology Department, ENETs Center of Excellence, Milan, Italy.|Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
authors.forename: Alice
authors.initials: A
authors.lastname: Indini
authors.affiliation: Medical Oncology Department, ENETs Center of Excellence, Milan, Italy.|Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
authors.forename: Barbara
authors.initials: B
authors.lastname: Formisano
authors.affiliation: Medical Oncology Department, ENETs Center of Excellence, Milan, Italy.|Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
authors.forename: Roberto
authors.initials: R
authors.lastname: Buzzoni
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D000068338:Everolimus / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D018358:Neuroendocrine Tumors / Q000188:drug therapy*; D015282:Octreotide / Q000008:administration & dosage; D017063:Outcome Assessment, Health Care / Q000379:methods / Q000706:statistics & numerical data; D016032:Randomized Controlled Trials as Topic; D016019:Survival Analysis
chemical_list: D000068338:Everolimus; D015282:Octreotide
keywords: everolimus; neuroendocrine tumors